CATX Perspective Therapeutics, Inc.
AMEXHealthcareAs of 2026-08-24 16:00
Why CATX matters now
Perspective Therapeutics, Inc. (CATX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.19 with -3.33% on the session and $363.8M in market capitalization.
The latest indexable market news headline is "Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. CATX" from Defense World.
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
AMEX
Beta
1.80
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.